Moxifloxacin plus standard first-line therapy in the treatment of pulmonary tuberculosis: A meta-analysis-Reference-Cited by-同舟云学术

Moxifloxacin plus standard first-line therapy in the treatment of pulmonary tuberculosis: A meta-analysis

Published:2015-07 Issue:4 Volume:95 Page:490-496
ISSN:1472-9792
Container-title:Tuberculosis
language:en
Short-container-title:Tuberculosis

Author:

Chen Zhi,Liang Jian-Qin,Wang Jin-He,Feng Shi-Sheng,Zhang Guang-Yu

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),Immunology,Microbiology

Reference20 articles.

1. 2004. World health report 2004: changing history. WHO. Geneva, Switzerland. http://www.who.int/whr/2004/en/report04_en.pdf.

2. 2007. Global tuberculosis control— surveillance, planning, financing. WHO. Geneva, Switzerland. http://www.who.int/tb/publications/global_report/2007/download_centre/en/index.html.

3. Low access to a highly effective therapy: a challenge for international tuberculosis control;Dye;Bull World Health Organ,2002

4. Confronting the scientific obstacles to global control of tuberculosis;Young;J Clin Invest,2008

5. Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the society of infectious diseases pharmacists;Hall;Pharmacotherapy,2009

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of quinolones as potential first line therapy in pulmonary tuberculosis: a meta-analysis;Folia Medica;2024-02-29

2. Chapitre 5: Le traitement de la tuberculose active;Canadian Journal of Respiratory, Critical Care, and Sleep Medicine;2023-11-02

3. Altered drug exposures of first-line TB drugs in a moxifloxacin-containing treatment regimen;The International Journal of Tuberculosis and Lung Disease;2022-08-01

4. Chapter 5: Treatment of tuberculosis disease;Canadian Journal of Respiratory, Critical Care, and Sleep Medicine;2022-03-24

5. Moxifloxacin is a safe and effective candidate agent for tuberculosis treatment: a meta-analysis of randomized controlled trials;Annals of Palliative Medicine;2021-02